Rocket Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $123.2M | $-47.6M | $-42.5M | $-50.3M | $-68.9M | $-61.3M | $-60.3M | $-66.7M |
| Depreciation & Amortization | $1.6M | $1.6M | $1.7M | $2.7M | $2.0M | $2.5M | $1.8M | $1.9M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $7.4M | $8.5M | $6.1M | $9.8M | $10.9M | $10.3M | $11.1M | $11.2M |
| Net Cash from Operating Activities | $-39.6M | $-45.4M | $-34.8M | $-50.4M | $-49.0M | $-55.8M | $-46.9M | $-52.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $8.0K | $93.0K | $80.0K | $-54.0K | $50.0K | $364.0K | $309.0K | $1.6M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $214.4M | $17.4M | $36.4M | $93.6M | $31.8M | $-58.0M | $-37.9M | $78.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $150.0K | $-1.0K | $0 | $-67.0K | $215.0K | $0 | $182.8M | $176.0K |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-39.6M | $-45.5M | $-34.9M | $-50.4M | $-49.0M | $-56.2M | $-47.3M | $-53.7M |